Advanced Search

 

Study ID Status Title Patient Level Data
HS2100275 Completed An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Study Listed on ClinicalStudyDataRequest.com
HS2101951 Completed Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients with Chickenpox - Open Uncontrolled Study.
HS210909 Completed Report of a Study to Evaluate the Bioequivalence of Single Doses of an Investigational Formulation of Valaciclovir Compared to the Standard Valaciclovir Tablet in Healthy Volunteers
HS210911 Completed A Randomised, Open-Label, Cross-Over, Single Dose Study to Evaluate the Pharmacokinetic Interaction Between Aciclovir 800mg and Mycophenolate Mofetil 1000mg and Between Valaciclovir 2000mg and Mycophenolate Mofetil 1000mg in Healthy Volunteers
HS210914 Completed An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children. Study Listed on ClinicalStudyDataRequest.com
HS210915 Completed An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection Study Listed on ClinicalStudyDataRequest.com
HS210916 Completed An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection Study Listed on ClinicalStudyDataRequest.com
HS230017 Completed An open-label, randomized, crossover study to determine subject treatment preference and efficacy of once daily valacyclovir 500 mg suppression therapy versus valacyclovir 500 mg twice daily treatment for recurrent genital HSV infections.
HS230018 Completed An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects Study Listed on ClinicalStudyDataRequest.com
HS230027 Completed A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes Study Listed on ClinicalStudyDataRequest.com
HS230028 Completed A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development Study Listed on ClinicalStudyDataRequest.com
HS240016 Completed CSF Penetration of Acyclovir and its Metabolites After High Dose Valacyclovir Administration
HS240017 Completed A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes Study Listed on ClinicalStudyDataRequest.com
HS240018 Completed A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes Study Listed on ClinicalStudyDataRequest.com
HS240021 Completed A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes Study Listed on ClinicalStudyDataRequest.com
HS2A3005 Completed An Open-Label, Pilot Study to Estimate the Effect on Subject Survival and the Safety of CMV Prophylaxis with IV Acyclovir Followed by Valacyclovir Hydrochloride or Ganciclovir in Allogeneic Bone Marrow Transplant Recipients
HS2A4004 Completed A Comparison of Oral VALTREX 500mg Twice Daily for Three or Five Days for Treatment of Recurrent Genital Herpes
HS2AB3009 Completed A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase) Study Listed on ClinicalStudyDataRequest.com
HS2B1001 Completed A study to compare the intraocular penetration of valaciclovir and aciclovir following multiple dose oral administration to patients undergoing cataract surgery.Extensive searching has revealed that no clinical study report is available for this study.
HS2B3010 Completed A Randomized, Double-Blind Study to Compare Valaciclovir 500mg Twice Daily Given for Three Days With the Standard Five Day Course as Episodic Treatment for Recurrent Genital Herpes
HS2B4001 Completed A Pharmacokinetic Study to Compare Aciclovir Plasma Exposures Attained with IV Zovirax® 5mg/kg t.d.s and Oral Valtrex® 1000mg t.d.s. in Neutropenic Non-HIV Patients
HS2B4005 Completed An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children
HSV Meta analyses Completed Meta analyses on pregnancy outcomes with respect to the effect of Herpes Simplex Virus (HSV) antigen and of the adjuvant (AS04)
HSV-003(JP) Completed Phase III Study of Valaciclovir Hydrochloride Tablets in Immunocompetent Patients With Herpes Simplex Virus Infections – Double-Blind Comparative With Aciclovir Tablets
HYT104152 Completed A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients with Cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.